...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Incorporating BCNU wafers into malignant glioma treatment: European case studies.
【24h】

Incorporating BCNU wafers into malignant glioma treatment: European case studies.

机译：欧洲案例研究：将BCNU晶片纳入恶性神经胶质瘤治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Carmustine (BCNU: N,N'-bis[2-chloroethyl]-N-nitrosourea) wafers are a local chemotherapeutic agent for the treatment of malignant glioma. They avoid the problems of high toxicity and short half-life associated with systemic delivery, and can bridge the traditional 'treatment gap' between surgery and subsequent conventional chemo- or radiotherapy. Clinical trials have demonstrated significant improvements in survival and quality of life for patients after complete tumour resection and BCNU wafer implantation. In practice, clinicians may use BCNU wafers in conjunction with other radio- and chemotherapies, in order to maximize the chance of a beneficial patient outcome. The purpose of these case reports is to exemplify how four experienced European clinicians employ BCNU wafers for the management of malignant glioma, and to illustrate how BCNU wafers can be effectively incorporated into treatment regimens. Four patients are described in whom BCNU wafers were implanted during the course of treatment for glioblastoma multiforme, the most severe and common type of malignant glioma. These include three patients with recurrent disease, and a single patient with a newly diagnosed tumour. All four patients received additional radio- and chemotherapy as appropriate. Treatment was well tolerated and patient survival from diagnosis ranged from 56 to 132 weeks. This compared favourably with the survival of approximately 58 weeks seen in the recent EORTC-NCIC clinical trial of combined radiotherapy with concomitant and adjuvant temozolomide. BCNU wafers are an effective means of increasing survival and quality of life in patients diagnosed with malignant glioma, and are a valuable addition to the overall multimodal treatment strategy for these tumours.
机译：卡莫司汀（BCNU：N，N'-双[2-氯乙基] -N-亚硝基脲）晶片是用于治疗恶性神经胶质瘤的局部化学治疗剂。它们避免了与全身给药相关的高毒性和半衰期短的问题，并可以弥合手术与随后的常规化学或放射疗法之间的传统“治疗鸿沟”。临床试验表明，在完成肿瘤切除和BCNU晶片植入后，患者的生存率和生活质量有了显着改善。在实践中，临床医生可以将BCNU晶片与其他放射线和化学疗法结合使用，以最大程度地提高患者获益的机会。这些病例报告的目的是举例说明四名经验丰富的欧洲临床医生如何使用BCNU晶片治疗恶性神经胶质瘤，并说明如何将BCNU晶片有效地纳入治疗方案。描述了四名在多形性胶质母细胞瘤（最严重和常见的恶性神经胶质瘤）治疗过程中植入BCNU晶片的患者。其中包括三名复发性疾病患者和一名新诊断肿瘤的患者。所有四名患者均适当接受了额外的放疗和化疗。治疗耐受性良好，诊断后患者的生存期为56至132周。与最近的EORTC-NCIC联合放疗联合替莫唑胺放疗的EORTC-NCIC临床试验中观察到的大约58周的生存期相比，这具有优势。 BCNU晶片是增加诊断为恶性神经胶质瘤患者生存率和生活质量的有效手段，并且是这些肿瘤整体多模态治疗策略的宝贵补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号